NASDAQ: EMBC · Medical Instruments & Supplies
Embecta (EMBC) fair value and price range
As of 14 Nov 2026, Faircurve's model values Embecta (EMBC) at $7.68 a share. The stock last closed at $6.25, which puts the model's fair value 22.9% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Embecta Corp.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $8.11 to $7.68 (-5.3%). The companies the model compares it with now trade on lower multiples: most of the move.
What the model makes of itThe price of $6.25 is 22.9% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextReports on 24 Nov 2026. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give EMBC?
The calibrated range for EMBC over 63 trading days is $6.14 to $9.12. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $0.00 to $22.01. In 53% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Embecta Corp. (EMBC) is a medical technology enterprise in healthcare, devoted to enhancing the quality of life and health outcomes for people living with diabetes.
On 14 Nov 2026, Faircurve's model put the fair value at $7.68 a share. The previous run, on 7 Nov 2026, gave $8.11, so the fair value moved -5.3%. In the model's words, the companies it compares Embecta with now trade on lower multiples: most of the move. The calibrated range over 63 trading days is $6.14 to $9.12. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade covers how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range is. It does not say whether the fair value is right.
Embecta scores 66 out of 100 on the model's overall quality score, a composite of six factors measured against comparable companies. Profitability stands out at 97, with ROIC of 26.3% against a peer median of -0.4%. Growth quality scores 26, with trailing revenue growth of -3.8% against a peer median of -5.8%. The balance sheet scores 8, with net debt to EBITDA of 4.84x. The model compares the company with STAAR Surgical, LeMaitre Vascular, DENTSPLY SIRONA, ICU Medical, Merit Medical Systems, Teleflex, AptarGroup and Envista Holdings.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does EMBC report earnings, and how has the stock reacted?
Embecta's next earnings report is scheduled for 24 Nov 2026. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across EMBC's last 8 reports, ignoring direction, was 18.5%.
How does EMBC score on business quality?
Embecta's overall quality score is 66 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 97 | 26.3%ROIC | -0.4% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 93 | 1.88xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 26 | -3.8%Revenue growth, trailing | -5.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 83 | 2.1%Net buybacks / market value | 4.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 8 | 4.84xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 42 | 5.7 ptsEBITDA margin downside volatility, 5y | 7.9 pts |
How does EMBC compare with similar companies?
The companies in medical instruments & supplies closest to Embecta in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| STAA STAAR Surgical Company | $26.01 | $24.60 | -5.4% | Fairly valued |
| LMAT LeMaitre Vascular, Inc. | $77.01 | $93.66 | +21.6% | Undervalued |
| XRAY DENTSPLY SIRONA Inc. | $8.95 | $13.35 | +49.2% | Undervalued |
| NVST Envista Holdings Corp | $24.03 | $25.54 | +6.3% | Low evidence grade |
| ICUI ICU Medical, Inc. | $181.87 | $202.62 | +11.4% | Fairly valued |
| MMSI Merit Medical Systems, Inc. | $86.35 | $82.63 | -4.3% | Fairly valued |
| TFX Teleflex Incorporated | $157.10 | $169.00 | +7.6% | Fairly valued |
| ATR AptarGroup, Inc. | $143.17 | $137.10 | -4.2% | Fairly valued |
What the comparable companies' multiples alone would give for EMBC, the peer-implied price, is $13.20 a share on this run. The fair value weighs that against the company's own multiple.
All medical instruments & supplies stocks ranked by gap to fair value
Embecta at a glance
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes.
- Market value
- $366M
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $1.1B
- Consensus revenue growth, next fiscal year
- -5.4%
- Analysts with estimates
- 3
- Beta to the US market
- 0.45
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Embecta on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for EMBC was $8.11. As of 14 Nov 2026 it is $7.68, a change of -5.3%. The companies the model compares it with now trade on lower multiples: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Embecta's valuation
Is Embecta stock undervalued or overvalued?
Faircurve's model puts EMBC's fair value at $7.68 a share against a last close of $6.25, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is EMBC's fair value?
$7.68 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $0.00 to $22.01.
What price range does the model give EMBC?
$6.14 to $9.12 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Embecta report earnings next?
The next report is scheduled for 24 Nov 2026. Companies can move their dates.
How much has EMBC moved on past earnings reports?
Across its last 8 reports the median two session move was 18.5%, ignoring direction. The largest was -61.5% around the report of 5 May 2026.
How confident is the model in this valuation?
The model's evidence grade for EMBC is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on EMBC
The model holds no idea open on EMBC today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on EMBC with their outcomes. A free account is enough.